|
Sodium- and chloride-dependent glycine transporter 1 is a protein that in humans is encoded by the ''SLC6A9'' gene.〔(【引用サイトリンク】 url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=6536 )〕 ==Selective inhibitors== Elevation of extracellular synaptic glycine concentration by blockade of GlyT1 has been hypothesized to potentiate NMDA receptor function in vivo and to represent a rational approach for the treatment of schizophrenia and cognitive disorders. Several drug candidates have reached clinical trials. * ASP2535〔Harada K, Nakato K, Yarimizu J, Yamazaki M, Morita M, Takahashi S, Aota M, Saita K, Doihara H, Sato Y, Yamaji T, Ni K, Matsuoka N. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-()-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. ''European Journal of Pharmacology''. 2012 Apr 20. PMID 22542656〕 * Bitopertin (RG1678), which has entered phase II trials for the treatment of schizophrenia * Org 25935 * PF-03463275 (in phase II trial) 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「glycine transporter 1」の詳細全文を読む スポンサード リンク
|